PBTH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
|Industry:||Biotechnology » Biotechnology|
|Compare:||SZSE:300381, XPAR:ALCLS, SZSE:002604, HKSE:00775, NAS:CLVS, NAS:CLDX » details|
|Traded in other countries:||M3D.Germany,|
PROLOR Biotech, Inc., formerly known as Modigene Inc., was formed on August 22, 2003 under the laws of the state of Nevada under the name LDG, Inc. It was formerly known as Modigene Inc. and changed its name to PROLOR Biotech, Inc. in June 2009. The Company develops proprietary versions of already-approved therapeutic proteins. Its technology, Carboxyl Terminal Peptide is used to develop new and proprietary versions of existing therapeutic proteins that have longer life spans than therapeutic proteins without CTP. The company's products under development include human growth hormone, which is used for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone; and factor IX that is offered to Hemophilia B patients to control blood clotting or coagulation. Its products under development also comprise anti-obesity peptide oxyntomodulin, factor VIIa, interferon ß and erythropoietin, and atherosclerosis and rheumatoid arthritis long-acting therapies.